Royalty Pharma Plc (RPRX) — Cash Flow-to-Debt Ratio
Royalty Pharma Plc (RPRX) has a Cash Flow-to-Debt Ratio of 0.08x as of March 2026, meaning its operating cash flow of $760.54 Million could theoretically repay 0% of its total liabilities ($9.88 Billion) in one year. Explore Royalty Pharma Plc long-term investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Royalty Pharma Plc Cash Flow-to-Debt Ratio (2002–2025)
Historical debt coverage capacity for Royalty Pharma Plc across 14 annual periods. Also explore total assets of Royalty Pharma Plc for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Royalty Pharma Plc (2002–2025)
Year-by-year debt coverage analysis for Royalty Pharma Plc. For market capitalisation and broader financial context, see Royalty Pharma Plc (RPRX) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.25x | $2.49 Billion | $9.91 Billion | ▼ -28.5% |
| 2024 | 0.35x | $2.77 Billion | $7.88 Billion | ▼ -25.9% |
| 2023 | 0.47x | $2.99 Billion | $6.30 Billion | ▲ +61.3% |
| 2022 | 0.29x | $2.14 Billion | $7.29 Billion | ▲ +6.0% |
| 2021 | 0.28x | $2.02 Billion | $7.27 Billion | ▼ -16.4% |
| 2020 | 0.33x | $2.03 Billion | $6.12 Billion | ▲ +25.7% |
| 2019 | 0.26x | $1.67 Billion | $6.31 Billion | ▲ +11.3% |
| 2018 | 0.24x | $1.62 Billion | $6.82 Billion | ▲ +15.5% |
| 2017 | 0.21x | $1.42 Billion | $6.90 Billion | ▲ +8039.6% |
| 2016 | 0.00x | $-15.58 Million | $6.02 Billion | ▲ +37.5% |
| 2015 | 0.00x | $-25.33 Million | $6.12 Billion | ▲ +100.0% |
| 2014 | -10.03x | $-29.33 Million | $2.92 Million | ▼ -148.7% |
| 2003 | 20.61x | $11.15 Million | $541.00K | ▲ +26.7% |
| 2002 | 16.27x | $8.45 Million | $519.00K | — |